Liver Manifestations in Covid-19 and the Influence of Pre-Existing Liver Disease in the Course of the Infection

Veloz, María Fernanda Guerra; Ruíz, P.; Ríos‐Villegas, Maria José; Bellido, Pilar Del Pino; Bravo‐Ferrer, José María; Cordero, Rocío Galvés; Herrera, María Lorena Cadena; Parrado, Carmen Vías; Muñoz, Francisco Bellido; Rodriguez, Francisco Vega; Álvarez, Ángel Caunedo; Soria, Isabel Carmona

doi:10.17235/reed.2020.7627/2020

Cited by 10 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of death in COVID‐19 patients with chronic liver disorders was compared with that in ones without the CLD in 15 studies. 19 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 42 In all of these studies, the mortality rate in patients with COVID‐19, and the CLD was higher than that in patients with COVID‐19, and without the CLD. 19 , 26 , 28 , 30 , 32 , 33 , 34 , 36 , 37 , 38 , 39 , 40 The cumulative RR after combining these studies was 1.52 (CI 95%: 1.46–1.57; I 2 : 86.14%) (Figure 2 ).…”

Section: Resultsmentioning

confidence: 92%

“…The risk of death in COVID‐19 patients with chronic liver disorders was compared with that in ones without the CLD in 15 studies 19,26,28–40,42 . In all of these studies, the mortality rate in patients with COVID‐19, and the CLD was higher than that in patients with COVID‐19, and without the CLD 19,26,28,30,32–34,36–40 . The cumulative RR after combining these studies was 1.52 (CI 95%: 1.46–1.57; I 2 : 86.14%) (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

“…The risk of need for ventilation in COVID‐19 patients who had the CLD was evaluated in 11 studies compared with those who did not have chronic liver disorders 26,29,30,32–34,37–40,42 . In all of these studies, the need for ventilation was higher in the group with the CLD 26,29,30,32–34,37–40 The frequency of need for ventilation was higher in the group of patients with COVID‐19 and liver disorders 42 . The cumulative RR after combining these studies was 1.53 (CI 95%: 1.46–1.60) with heterogeneity ( I 2 ) equal to 0.2% (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies

Afraie

Mohammadzedeh

Azami

et al. 2022

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction:The aim of this review was to combine the results of published cohort studies to determine the exact association between chronic liver disorders, and the severe form of COVID-19, and its associated complications. Methods: This meta-analysis employed a keyword search (COVID-19 and chronic liver disorders) using PubMed (Medline), Scopus, Web of Sciences, and Embase (Elsevier). All articles related from January 2019 to May 2022 were reviewed. The STATA software was used for analysis. Results: The risk of death in COVID-19 patients with chronic liver disorders was higher than in ones without the chronic liver disease (RR: 1.52; CI 95%: 1.46-1.57; I 2 : 86.14%). Also, the risk of acute respiratory distress syndrome (ARDS) and hospitalization in COVID-19 patients with chronic liver disorders was higher than in ones without the chronic liver disease ([RR: 1.65; CI 95%: 1.09-2.50; I 2 : 0.00%] and [RR: 1.39; CI 95%: 1.23-1.58; I 2 : 0.20%]). Also, the meta-analysis showed cough, headache, myalgia, nausea, diarrhea, and fatigue

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies

Afraie

Mohammadzedeh

Azami

et al. 2022

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…Other pre-existing conditions that have been shown to exacerbate COVID-19 symptoms might have the same origins; for instance, chronic kidney disease is associated with oxidative stress and elevated expression of ACE-2 and cytokines, including IL-6 and CRP ( 2 ). In addition, the liver is a major source of proteins involved in innate and adaptive immunity, while cirrhosis-associated immune dysfunction, combined with systemic and hepatic inflammation in patients with chronic liver disease, might amplify COVID-19 symptoms ( 126 , 129 ). Thus, liver injury in COVID-19 patients might be immune-mediated rather than a result of direct cytopathic damage ( 130 ).…”

Section: Covid-19 and The Most Common Comorbiditiesmentioning

confidence: 99%

COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes

et al. 2022

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated symptoms, named coronavirus disease 2019 (COVID-19), have rapidly spread worldwide, resulting in the declaration of a pandemic. When several countries began enacting quarantine and lockdown policies, the pandemic as it is now known truly began. While most patients have minimal symptoms, approximately 20% of verified subjects are suffering from serious medical consequences. Co-existing diseases, such as cardiovascular disease, cancer, diabetes, and others, have been shown to make patients more vulnerable to severe outcomes from COVID-19 by modulating host–viral interactions and immune responses, causing severe infection and mortality. In this review, we outline the putative signaling pathways at the interface of COVID-19 and several diseases, emphasizing the clinical and molecular implications of concurring diseases in COVID-19 clinical outcomes. As evidence is limited on co-existing diseases and COVID-19, most findings are preliminary, and further research is required for optimal management of patients with comorbidities.

show abstract

“…As per our inclusion criteria, all cohort studies were based in Europe and included 23 studies from Spain (14, 16, 17, 22, 28, 29, 32, 33, 35, 50, 54, 57-59, 64, 67, 70, 80, 89, 92, 96, 97, 101), 22 studies from Italy(13, 19, 21, 23, 25, 30, 38, 39, 45, 47, 48, 55, 56, 61, 62, 68, 71, 77, 79, 90, 91, 93), 15 studies from France (20, 24, 27, 31, 40, 41, 43, 53, 60, 63, 65, 74, 76, 86, 99), ten studies from the UK (26, 34, 44, 49, 52, 66, 72, 75, 87, 98), four included patients from more than one country (69, 73, 88, 94), three from Germany (46, 51, 78), two studies from Sweden(36, 100), two from Denmark (42, 83) and one study from Belgium (81), Finland (5), the Netherlands (18), Norway (85) and Poland (37). The diagnosis of COVID-19 was made mainly with a PCR test, except for in five studies in which the diagnosis was made with the ICD Classification (20, 24, <...>…”

Section: Resultsmentioning

confidence: 99%

Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe

Vardavas

Mathioudakis

Nikitara

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: As mortality from COVID-19 is strongly age-dependent, we aimed to identify population subgroups at an elevated risk for adverse outcomes from COVID-19 using age/gender-adjusted data from European cohort studies with the aim to identify populations that could potentially benefit from booster vaccinations. Methods: We performed a systematic literature review and meta-analysis to investigate the role of underlying medical conditions as prognostic factors for adverse outcomes due to SARS-CoV-2, including death, hospitalisation, Intensive Care Unit (ICU) admission, and mechanical ventilation within three separate settings (community, hospital and ICU). Cohort studies that reported at least age and gender-adjusted data from Europe were identified through a search of peer-reviewed articles published until 11th June 2021 in Ovid Medline and Embase. Results are presented as Odds Ratios (ORs) with 95% confidence intervals (95%C.I.) and absolute risk differences (RD) in deaths per 1,000 COVID-19 patients. Findings: We included 88 cohort studies with age/gender adjusted data from 6,653,207 SARS-CoV-2 patients from Europe. Hospital-based mortality was associated with high and moderate certainty evidence for solid organ tumours, diabetes mellitus, renal disease, arrhythmia, ischemic heart disease, liver disease, and obesity, while a higher risk, albeit with low certainty, was noted for chronic obstructive pulmonary disease and heart failure. Community-based mortality was associated with a history of heart failure, stroke, diabetes, and end-stage renal disease. Evidence of high/moderate certainty revealed a strong association between hospitalisation for COVID-19 and solid organ transplant recipients, sleep apnoea, diabetes, stroke, and liver disease. Interpretation: The results confirmed the strong association between specific prognostic factors and mortality and hospital admission. Prioritisation of booster vaccinations and the implementation of non-pharmaceutical protective measures for these populations may contribute to a reduction in COVID-19 mortality, ICU and hospital admissions. Funding: European Centre for Disease Prevention and Control (ECDC) under specific contract No. 10 ECD.11843 within Framework contract ECDC/2019/001 Lot 1B.

show abstract

Liver Manifestations in Covid-19 and the Influence of Pre-Existing Liver Disease in the Course of the Infection

Cited by 10 publications

References 23 publications

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies

COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes

Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe

Contact Info

Product

Resources

About